Lab-grown brain tumor organoids developed from a patient’s own glioblastoma, the most aggressive and common form of brain cancer, may hold the answers on how to best treat it, according to a new study. “While we’ve made important strides in glioblastoma research, preclinical and clinical challenges persist, keeping us from getting closer to more effective… Read more

A protein known as transcriptional enhancer factor TEF-1 (TEAD1) is an important regulator of tumor migration in glioblastoma, the most common brain tumor in adults, and deactivating this protein may stop tumor cells from migrating away from the main tumor mass, according to new research from the Icahn School of Medicine at Mount Sinai. The… Read more

A specific type of cell essential to the ability of olfactory neurons to regenerate may be genetically engineered to deliver anticancer therapy to the dangerous brain tumors called glioblastomas, researchers from Massachusetts General Hospital (MGH) report. The team used olfactory ensheathing cells to deliver an anticancer agent only to tumor cells and how the treatment… Read more

Patient-derived glioblastoma cells with telomerase reverse transcriptase (TERT) promoter mutations depend on a particular form of a protein called GABP for their survival, UC San Francisco researchers have discovered. The finding reveals how a mutation in the gene regulator – the third most common mutation among all human cancers and the most common mutation in… Read more

A new strategy to overcome one of the main obstacles in the treatment of brain cancer — access to the tumor – has been developed by an international team led by researchers at Baylor College of Medicine. Under the influence of cancer, the blood-brain barrier diverts immune T cells that attempt to enter the brain… Read more